Research location
Celebration
Florida, United States
Advertisement
Research activity in Celebration
Florida, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 69 trials and 72 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Celebration
69 linked trials · page 1 of 2Exploring the Potential of Robotic Telesurgery in Remote SettingsNCT07130708 · 2025-06-14 · 1 site observation
RECRUITING
SMP-3124LP in Adults With Advanced Solid TumorsNCT06526819 · 2024-08-14 · 1 site observation
RECRUITING
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenTNCT06059638 · 2023-12-27 · 1 site observation
RECRUITING
KO-2806 Monotherapy and Combination Therapies in Advanced Solid TumorsNCT06026410 · 2023-10-18 · 1 site observation
RECRUITING
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid TumorsNCT05914116 · 2023-08-17 · 1 site observation
RECRUITING
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid TumorsNCT05948865 · 2023-06-06 · 1 site observation
RECRUITING
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid TumorsNCT05592626 · 2023-01-04 · 1 site observation
RECRUITING
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid TumorsNCT05176483 · 2021-12-14 · 1 site observation
RECRUITING
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7NCT04613596 · 2020-12-02 · 1 site observation
RECRUITING
A Study of Mosliciguat in PH-ILDNCT06635850 · 2024-10-29 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study With NKT3447 for Adults With Advanced/Metastatic Solid TumorsNCT06264921 · 2024-02-23 · 1 site observation
TERMINATED
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary FibrosisNCT06025578 · 2023-10-25 · 1 site observation
ACTIVE_NOT_RECRUITING
A First-in-human Study to Learn How Safe the Study Treatment BAY2862789 is, to Find the Best Dose, How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, and How it Acts on Different Tumors in Participants With Advanced Solid TumorsNCT05858164 · 2023-08-07 · 1 site observation
COMPLETED
A Study of CDX-585 in Patients With Advanced MalignanciesNCT05788484 · 2023-05-11 · 1 site observation
COMPLETED
PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 MutationNCT05639751 · 2023-05-02 · 1 site observation
COMPLETED
BioDFence® G3 For Full Nerve-Sparing Robotic-Assisted Radical ProstatectomyNCT05363644 · 2023-04-01 · 1 site observation
WITHDRAWN
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2NCT05514717 · 2023-01-24 · 1 site observation
TERMINATED
A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid TumorsNCT05538572 · 2022-12-27 · 1 site observation
COMPLETED
Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) MutationsNCT05364073 · 2022-06-30 · 1 site observation
ACTIVE_NOT_RECRUITING
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean StudyNCT05053152 · 2022-04-20 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of PRT2527 in Participants With Advanced Solid TumorsNCT05159518 · 2022-02-14 · 1 site observation
COMPLETED
A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid TumorsNCT05194072 · 2022-01-12 · 2 site observations
TERMINATED
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD TrialNCT04457596 · 2021-03-02 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)NCT04585815 · 2020-11-10 · 2 site observations
TERMINATED
Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902)NCT04314089 · 2020-06-09 · 1 site observation
COMPLETED
SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)NCT04291079 · 2020-04-23 · 1 site observation
COMPLETED
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted TherapyNCT04266249 · 2020-03-13 · 1 site observation
ACTIVE_NOT_RECRUITING
Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast CancerNCT03199885 · 2019-04-05 · 1 site observation
TERMINATED
A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid TumorsNCT03854227 · 2019-03-14 · 2 site observations
TERMINATED
Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid TumorsNCT03821935 · 2019-02-21 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD7594 Administered Once Daily by Inhalation in Asthmatic SubjectsNCT03622112 · 2019-01-02 · 1 site observation
COMPLETED
Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung CancerNCT03539536 · 2018-10-10 · 1 site observation
ACTIVE_NOT_RECRUITING
A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)NCT03478696 · 2018-06-25 · 1 site observation
COMPLETED
Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast CancerNCT03414970 · 2018-03-12 · 1 site observation
ACTIVE_NOT_RECRUITING
Evaluation of a Blood Biomarker to Try and Distinguish Between the Presence or Absence of Aggressive Prostate CancerNCT03256630 · 2018-01-10 · 1 site observation
TERMINATED
Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled AsthmaNCT03347279 · 2017-11-23 · 1 site observation
COMPLETED
Retrospective Chart Review of First-time Opsumit® (Macitentan) Users in the United StatesNCT03197688 · 2017-08-03 · 1 site observation
COMPLETED
Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by SurgeryNCT03070886 · 2017-04-05 · 1 site observation
ACTIVE_NOT_RECRUITING
Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFENCT02630316 · 2017-02-03 · 1 site observation
COMPLETED
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast CancerNCT02954874 · 2017-01-18 · 1 site observation
ACTIVE_NOT_RECRUITING
Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation TherapyNCT02927249 · 2017-01-06 · 1 site observation
TERMINATED
A Registry for Patients Taking UptraviNCT03278002 · 2016-11-01 · 1 site observation
COMPLETED
An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFENCT02633293 · 2016-09-15 · 1 site observation
TERMINATED
Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)NCT02796651 · 2016-06-30 · 1 site observation
COMPLETED
A Case-Control Study to Verify Diagnostic Performance of AminoIndex™ TechnologyNCT02512757 · 2015-08-13 · 1 site observation
COMPLETED
Study to Assess Functionality, Reliability, and Performance of a Pre-filled Syringe With Benralizumab Administered at HomeNCT02417961 · 2015-04-27 · 1 site observation
COMPLETED
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)NCT02201992 · 2015-03-23 · 1 site observation
ACTIVE_NOT_RECRUITING
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)NCT02193282 · 2015-02-11 · 1 site observation
ACTIVE_NOT_RECRUITING
Circulating Tumor DNA Exposure in Peripheral BloodNCT03517332 · 2015-01-01 · 1 site observation
UNKNOWN
A Prospective, Multi-center, Single-arm Study of the Stomach, Intestinal and Pylorus Sparing (SIPS) ProcedureNCT02275208 · 2014-12-11 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.